Simcere Pharmaceutical Group Limited
2096
주식 순위
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
주가
$1.32
시가총액
$3.40B
변동 (1일)
-4.51%
변동 (1년)
-19.88%
국가
CN
거래 Simcere Pharmaceutical Group Limited (2096)
카테고리
Healthcare
Simcere Pharmaceutical Group Limited (2096)의 수익
2026 기준 수익 TTM: 0
Simcere Pharmaceutical Group Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Simcere Pharmaceutical Group Limited의 수익 기록 (2012 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2025 | $216.44M | 92.69% |
| 2024 | $112.33M | 7.44% |
| 2023 | $104.55M | -18.80% |
| 2022 | $128.76M | -41.62% |
| 2021 | $220.55M | 78.96% |
| 2020 | $123.24M | -20.67% |
| 2019 | $155.36M | 15.03% |
| 2018 | $135.06M | 76.71% |
| 2017 | $76.43M | -2,485.00% |
| 2012 | $-3.20M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
